Chemed Future Growth

Future criteria checks 1/6

Chemed is forecast to grow earnings and revenue by 9.6% and 6.7% per annum respectively while EPS is expected to grow by 10.5% per annum.

Key information

9.6%

Earnings growth rate

10.5%

EPS growth rate

Healthcare earnings growth17.1%
Revenue growth rate6.7%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Mar 2025

Recent future growth updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01
The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

Here's Why We Think Chemed (NYSE:CHE) Is Well Worth Watching

Apr 07
Here's Why We Think Chemed (NYSE:CHE) Is Well Worth Watching

Chemed Corporation's (NYSE:CHE) Intrinsic Value Is Potentially 61% Above Its Share Price

Mar 21
Chemed Corporation's (NYSE:CHE) Intrinsic Value Is Potentially 61% Above Its Share Price

Chemed Corporation's (NYSE:CHE) Popularity With Investors Is Clear

Mar 06
Chemed Corporation's (NYSE:CHE) Popularity With Investors Is Clear

Investors Shouldn't Overlook The Favourable Returns On Capital At Chemed (NYSE:CHE)

Jan 03
Investors Shouldn't Overlook The Favourable Returns On Capital At Chemed (NYSE:CHE)

With EPS Growth And More, Chemed (NYSE:CHE) Makes An Interesting Case

Dec 18
With EPS Growth And More, Chemed (NYSE:CHE) Makes An Interesting Case

Is There An Opportunity With Chemed Corporation's (NYSE:CHE) 25% Undervaluation?

Dec 03
Is There An Opportunity With Chemed Corporation's (NYSE:CHE) 25% Undervaluation?

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01
The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

Oct 29
Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Aug 26
Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future
author-image

Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward

Aug 25 Strategic acquisitions, such as Covenant Health, and aggressive hiring in VITAS are poised to enhance Chemed's revenue and net margins through improved operational efficiency.

Chemed Remains A Buy On Long-Term Economics

Aug 16

Chemed Corporation's (NYSE:CHE) Shares May Have Run Too Fast Too Soon

Jul 19
Chemed Corporation's (NYSE:CHE) Shares May Have Run Too Fast Too Soon

Chemed: Growth Does Not Justify The Current Stock Price

May 20

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

May 14
Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Apr 26
Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Nov 30

Chemed - Showcasing Why It's So Reliable

Aug 26

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

Aug 13

Earnings and Revenue Growth Forecasts

NYSE:CHE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272,970N/AN/AN/A1
12/31/20262,800366N/AN/A3
12/31/20252,625335N/AN/A3
12/31/20242,431302368417N/A
9/30/20242,377302313361N/A
6/30/20242,336301253300N/A
3/31/20242,293283302354N/A
12/31/20232,264273273330N/A
9/30/20232,225245259322N/A
6/30/20232,187226280345N/A
3/31/20232,165240208269N/A
12/31/20222,135250253310N/A
9/30/20222,129262220273N/A
6/30/20222,141277284334N/A
3/31/20222,142267249303N/A
12/31/20212,139269250309N/A
9/30/20212,132308271332N/A
6/30/20212,121303283344N/A
3/31/20212,091329450507N/A
12/31/20202,080319430489N/A
9/30/20202,069271410466N/A
6/30/20202,021263413470N/A
3/31/20201,992231258317N/A
12/31/20191,939220248301N/A
9/30/20191,874209238294N/A
6/30/20191,837201218275N/A
3/31/20191,806205241296N/A
12/31/20181,783206234287N/A
9/30/20181,753206N/A202N/A
6/30/20181,727190N/A183N/A
3/31/20181,700113N/A159N/A
12/31/20171,66798N/A162N/A
9/30/20171,64276N/A198N/A
6/30/20171,61767N/A162N/A
3/31/20171,592114N/A197N/A
12/31/20161,577109N/A135N/A
9/30/20161,572106N/A187N/A
6/30/20161,566108N/A175N/A
3/31/20161,557111N/A166N/A
12/31/20151,543110N/A172N/A
9/30/20151,524110N/A172N/A
6/30/20151,496106N/A135N/A
3/31/20151,475103N/A134N/A
12/31/20141,45699N/A110N/A
9/30/20141,42592N/A66N/A
6/30/20141,40885N/A111N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CHE's forecast earnings growth (9.6% per year) is above the savings rate (2.8%).

Earnings vs Market: CHE's earnings (9.6% per year) are forecast to grow slower than the US market (13.5% per year).

High Growth Earnings: CHE's earnings are forecast to grow, but not significantly.

Revenue vs Market: CHE's revenue (6.7% per year) is forecast to grow slower than the US market (8.3% per year).

High Growth Revenue: CHE's revenue (6.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CHE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/16 12:10
End of Day Share Price 2025/04/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chemed Corporation is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Adam FeinsteinBarclays
Joanna Sylvia GajukBofA Global Research